Skip to main content

Cogent Biosciences, Inc 8-K, filed Nov 5, 2026

Cogent Biosciences, Inc. (COGT)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Cogent Biosciences, Inc filed this 8-K on November 5, 2026.

Cogent Biosciences reported a $111.4 million 2026 third-quarter net loss and $791.1 million cash. Bezuclastinib FDA decision dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvSM and June 29, 2027 for AdvSM. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits